AEterna Zentaris (AEterna Zentaris) Forward Dividend Yield % : 0.00% (As of Apr. 30, 2024)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Forward Dividend Yield %?

As of today (2024-04-30), the Forward Annual Dividend Yield of AEterna Zentaris is 0.00%.

As of today (2024-04-30), the Trailing Annual Dividend Yield of AEterna Zentaris is 0.00%.

AEZS's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.45
* Ranked among companies with meaningful Forward Dividend Yield % only.

AEterna Zentaris's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of AEterna Zentaris was -6.70% per year. The lowest was -6.70% per year. And the median was -6.70% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of AEterna Zentaris's Forward Dividend Yield %

For the Biotechnology subindustry, AEterna Zentaris's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Forward Dividend Yield % falls into.

AEterna Zentaris Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

AEterna Zentaris (NAS:AEZS) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

AEterna Zentaris Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.